×
Customize
?
Start
Cancer Types
Quick Links
Events
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Leukemia
Katie Vandrilla
Conor Killmurray
The COVID-19 pandemic will continue to alter how patients with cancer receive their treatment, and experts within the United States who saw the virus strike early are offering their advice to other hospitals just starting to feel the effects.
Kristie L. Kahl
Patients with relapsed or refractory CD19-positive cancers experienced complete responses with no major side effects following treatment with CAR-NK cell therapy.
Katie Kosko
Patients with acute myeloid leukemia whose disease has relapsed or become resistant to treatment saw a benefit with a combination of Opdivo and Vidaza.
Jessica Skarzynski
Patients with acute myeloid leukemia often have to undergo transplant during treatment but are susceptible to other side effects, but new research indicates that the use of immunotherapy after thee treatments can improve patient outcomes.
Jessica Skarzynski
Here are the latest highlights from the first CURE Hematology Special Edition issue for 2020.
Debu Tripathy, M.D.
Targeted therapies have changed the landscape of cancer care, and now, hope for remission is a possibility for certain patients with acute myeloid leukemia with new approved therapies.
A wave of new targeted therapies expands the options in acute myeloid leukemia.
Katie Kosko
Newer medications that displace chemotherapy aim directly at mutations in the Bruton tyrosine kinase gene and help patients with CLL live longer.
Ryan McDonald
Treatment options for patients with acute myeloid leukemia are limited, especially for older patients, but a new trial looking at novel therapy combinations could change the treatment landscape.